These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 31513432)

  • 1. Induced degradation of protein kinases by bifunctional small molecules: a next-generation strategy.
    Groppe JC
    Expert Opin Drug Discov; 2019 Dec; 14(12):1237-1253. PubMed ID: 31513432
    [No Abstract]   [Full Text] [Related]  

  • 2. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
    Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
    Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted protein degradation by PROTACs.
    Neklesa TK; Winkler JD; Crews CM
    Pharmacol Ther; 2017 Jun; 174():138-144. PubMed ID: 28223226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rise and rise of protein degradation: Opportunities and challenges ahead.
    Hughes SJ; Testa A; Thompson N; Churcher I
    Drug Discov Today; 2021 Dec; 26(12):2889-2897. PubMed ID: 34419629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.
    Smith BE; Wang SL; Jaime-Figueroa S; Harbin A; Wang J; Hamman BD; Crews CM
    Nat Commun; 2019 Jan; 10(1):131. PubMed ID: 30631068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PROTACs- a game-changing technology.
    Konstantinidou M; Li J; Zhang B; Wang Z; Shaabani S; Ter Brake F; Essa K; Dömling A
    Expert Opin Drug Discov; 2019 Dec; 14(12):1255-1268. PubMed ID: 31538491
    [No Abstract]   [Full Text] [Related]  

  • 7. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
    An S; Fu L
    EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein degradation: a validated therapeutic strategy with exciting prospects.
    Lebraud H; Heightman TD
    Essays Biochem; 2017 Nov; 61(5):517-527. PubMed ID: 28970340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New strategy for renal fibrosis: Targeting Smad3 proteins for ubiquitination and degradation.
    Wang X; Feng S; Fan J; Li X; Wen Q; Luo N
    Biochem Pharmacol; 2016 Sep; 116():200-9. PubMed ID: 27473774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phenotypic Approach for the Identification of New Molecules for Targeted Protein Degradation Applications.
    Stacey P; Lithgow H; Lewell X; Konopacka A; Besley S; Green G; Whatling R; Law R; Röth S; Sapkota GP; Smith IED; Burley GA; Harling J; Benowitz AB; Queisser MA; Muelbaier M
    SLAS Discov; 2021 Aug; 26(7):885-895. PubMed ID: 34041938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PROTACs: A novel strategy for cancer therapy.
    Liu J; Ma J; Liu Y; Xia J; Li Y; Wang ZP; Wei W
    Semin Cancer Biol; 2020 Dec; 67(Pt 2):171-179. PubMed ID: 32058059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.
    Gu S; Cui D; Chen X; Xiong X; Zhao Y
    Bioessays; 2018 Apr; 40(4):e1700247. PubMed ID: 29473971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action.
    Riching KM; Mahan S; Corona CR; McDougall M; Vasta JD; Robers MB; Urh M; Daniels DL
    ACS Chem Biol; 2018 Sep; 13(9):2758-2770. PubMed ID: 30137962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
    Zhang C; Han XR; Yang X; Jiang B; Liu J; Xiong Y; Jin J
    Eur J Med Chem; 2018 May; 151():304-314. PubMed ID: 29627725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frontiers in PROTACs.
    Hughes GR; Dudey AP; Hemmings AM; Chantry A
    Drug Discov Today; 2021 Oct; 26(10):2377-2383. PubMed ID: 33872800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of targeted protein degradation therapeutics.
    Chamberlain PP; Hamann LG
    Nat Chem Biol; 2019 Oct; 15(10):937-944. PubMed ID: 31527835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
    Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
    Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring and deciphering protein degradation pathways inside cells.
    Daniels DL; Riching KM; Urh M
    Drug Discov Today Technol; 2019 Apr; 31():61-68. PubMed ID: 31200861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydrophobic tagging of small molecules: an overview of the literature and future outlook.
    Zhou Y; Zhou F; Xu S; Shi D; Ding D; Wang S; Poongavanam V; Tang K; Liu X; Zhan P
    Expert Opin Drug Discov; 2024 Jul; 19(7):799-813. PubMed ID: 38825802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-Molecule PROTACS: New Approaches to Protein Degradation.
    Toure M; Crews CM
    Angew Chem Int Ed Engl; 2016 Feb; 55(6):1966-73. PubMed ID: 26756721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.